Monopar Therapeutics
Datakwaliteit: 100%
MNPR
Nasdaq
Manufacturing
Chemicals
€ 57,28
▼
€ 0,75
(-1,29%)
Marktkapitalisatie: 385,07 M
Prijs
€ 57,28
Marktkapitalisatie
385,07 M
Dagbereik
€ 55,90 — € 58,39
52-Weeksbereik
€ 28,40 — € 105,00
Volume
315.592
Openen € 57,33
50D / 200D Gem.
€ 58,30
1,76% below
50D / 200D Gem.
€ 61,03
6,15% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -12,20 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-14,16%
Boven sectorgemiddelde (-53,47%)
ROIC-13,61%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio56,10
Interest CoverageN/A
Waardering
PE (TTM)
-28,07
Onder sectorgemiddelde (-1,47)
P/B Ratio2,72
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -28,1 | -1,5 |
| P/B | 2,7 | 1,6 |
| ROE % | -14,2 | -53,5 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0,0 | Net Income (TTM) | -13,72 M |
| ROE | -14,16% | ROA | -13,85% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -12,20 M |
| ROIC | -13,61% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 56,10 |
| Interest Coverage | N/A | Asset Turnover | 0,00 |
| Working Capital | 141,52 M | Tangible Book Value | 141,56 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -28,07 | Forward P/E | N/A |
| P/B Ratio | 2,72 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -3,17% | ||
| Market Cap | 385,07 M | Enterprise Value | 257,39 M |
| Per Share | |||
| EPS (Diluted TTM) | N/A | Revenue / Share | 0,00 |
| FCF / Share | -1,82 | OCF / Share | -1,82 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 88,95% |
| SBC-Adj. FCF | -16,13 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0,0 | 0,0 | 0,0 | — | — |
| Net Income | -13,72 M | -15,59 M | -8,40 M | -10,52 M | -9,10 M |
| EPS (Diluted) | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -16,70 M | -16,16 M | -8,83 M | -10,54 M | -9,13 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 9,90 M | 13,01 M | 5,60 M | 7,59 M | 6,49 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | 429.039,0 | 21.239,0 | 24.024,0 |
| Income Tax | 800,0 | 800,0 | 800,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 140,72 M | 60,29 M | 7,35 M | 13,23 M | 20,52 M |
| Total Liabilities | 2,89 M | 5,25 M | 1,76 M | 3,14 M | 1,58 M |
| Shareholders' Equity | 137,83 M | 55,04 M | 5,59 M | 10,09 M | 18,94 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 61,83 M | 45,82 M | 7,27 M | 8,19 M | 20,30 M |
| Current Assets | 140,46 M | 60,29 M | 7,33 M | 13,17 M | 20,52 M |
| Current Liabilities | 2,74 M | — | 1,76 M | 3,13 M | — |
{"event":"ticker_viewed","properties":{"ticker":"MNPR","listing_kind":"stock","pathname":"/stocks/mnpr","exchange":"Nasdaq","country":"US"}}